X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
NYX-2925 did not achieve statistically significant separation from placebo on the study’s primary endpoint, which assessed the change from baseline in average daily pain on the numeric rating scale (NRS) during week 12.
Lead Product(s): NYX-2925
Therapeutic Area: Musculoskeletal Product Name: NYX-2925
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 12, 2022
Details:
NYX-2925, an oral NMDA receptor positive allosteric modulator did not achieve statistically significant separation from placebo on study’s primary endpoint, which assessed change from baseline in average daily pain on numeric rating scale (NRS) during week 12.
Lead Product(s): NYX-2925
Therapeutic Area: Neurology Product Name: NYX-2925
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2022
Details:
The Phase 2b study enrollment completed with 305 patients and, is evaluating the efficacy and safety of NYX-2925, a novel oral NMDA receptor positive allosteric modulator in patients with fibromyalgia.
Lead Product(s): NYX-2925
Therapeutic Area: Musculoskeletal Product Name: NYX-2925
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2022
Details:
NYX-2925, NMDA receptor positive allosteric modulator currently under evaluation in Phase 2b study in patients with painful DPN and fibromyalgia has also exhibited favorable safety and tolerability profile across a wide dose range in clinical studies.
Lead Product(s): NYX-2925
Therapeutic Area: Neurology Product Name: NYX-2925
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 09, 2022
Details:
In clinical studies, NYX-2925 has demonstrated activity that aects central pain processing, resulting in alleviation of pain and other symptoms associated with chronic pain conditions.
Lead Product(s): NYX-2925
Therapeutic Area: Neurology Product Name: NYX-2925
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2021
Details:
Under the research agreement, investigators within the institute will partner with Aptinyx, which is developing novel therapies for neurologic disorders including NYX-2925, an oral small molecule NMDA receptor modulator in development for the treatment of chronic pain.
Lead Product(s): NYX-2925
Therapeutic Area: Neurology Product Name: NYX-2925
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Rosalind Franklin University of Medicine and Science
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 22, 2021
Details:
The funds will provide general growth as Aptinyx advances its late-stage clinical pipeline of novel NMDA modulators which includes NYX-2925, a novel, oral small molecule in development for the treatment of chronic pain.
Lead Product(s): NYX-2925
Therapeutic Area: Neurology Product Name: NYX-2925
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: K2 HealthVentures
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing September 16, 2021
Details:
Aptinyx has re-activated study sites and recommenced patient recruitment in a Phase 2 study of NYX-2925 in patients with fibromyalgia. Enrollment in the study had been suspended in March 2020 due to the escalation of the COVID-19 pandemic in the United States.
Lead Product(s): NYX-2925
Therapeutic Area: Musculoskeletal Product Name: NYX-2925
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2020
Details:
Aptinyx intends to use the net proceeds to advance the preclinical and clinical development of its novel NMDA receptor modulators, including NYX-2925, NYX-783, and NYX-458.
Lead Product(s): NYX-2925
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cowen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering January 09, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
